Literature DB >> 12870138

Close monitoring and lifetime follow-up is optimal for patients with a history of melanoma.

David F Christianson1, Clay M Anderson.   

Abstract

Malignant melanoma, a potentially lethal form of skin cancer, is becoming more common each year in the United States and worldwide. The cure rate, however, is also increasing due to better education, earlier detection, and more effective treatment. Thus, there are more melanoma survivors who are at risk for recurrence of melanoma and also a second primary. Because there are few prospective screening and surveillance results in the medical literature, recommendations for follow-up of melanoma survivors have been based on the natural history of the disease, physical examinations, laboratory tests, and radiologic evaluations.

Entities:  

Mesh:

Year:  2003        PMID: 12870138     DOI: 10.1016/s0093-7754(03)00097-6

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  4 in total

1.  Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients.

Authors:  Sapoznik Sivan; Faranesh Suzan; Ortenberg Rona; Hamburger Tamar; Barak Vivian; Peretz Tamar; Schachter Jacob; Markel Gal; Lotem Michal
Journal:  Clin Dev Immunol       Date:  2012-01-16

2.  Health profiles of 996 melanoma survivors: the M. D. Anderson experience.

Authors:  Charles Stava; Martha Beck; L Todd Weiss; Adriana Lopez; Rena Vassilopoulou-Sellin
Journal:  BMC Cancer       Date:  2006-04-18       Impact factor: 4.430

3.  Outpatient Follow-up and Secondary Prevention for Melanoma Patients.

Authors:  Ryan G Gamble; Daniel Jensen; Andrea L Suarez; Anne H Hanson; Lauren McLaughlin; Jodi Duke; Robert P Dellavalle
Journal:  Cancers (Basel)       Date:  2010-06-07       Impact factor: 6.639

Review 4.  Follow-up in melanoma patients.

Authors:  Piotr Rutkowski; Iwona Lugowska
Journal:  Memo       Date:  2014-06-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.